Use of antipruritic and rehydrating foams on localized lesions of atopic dermatitis in dogs: a small-scale pilot and comparative double-blinded study.
There is a lack of controlled studies evaluating the efficacy of topical nonsteroidal agents for the treatment of canine atopic dermatitis (cAD). To compare the clinical efficacy of a commercial foam product (mousse), previously demonstrated to be effective in cAD (Foam A) with a foam/mousse containing components from plant extracts (Foam B). Eight client-owned dogs with nonseasonal mild/moderate cAD. Dogs were treated twice weekly with either Foam A or Foam B for 14 days and after a wash-out period of 14 days received the other foam in a randomized blinded study. Criteria evaluated included skin lesions [Canine Atopic Dermatitis Lesion Index (CADLI)], pruritus Visual Analog Scale (pVAS)], cosmetic evaluation and overall global product assessment by the owner and the investigator. A significant improvement was noted for both treatment groups for both CADLI and pVAS scores (37.5% and 26.09%, respectively, for Foam A; 41.9% and 32.6%, respectively, for Foam B) (P < 0.05). Owner and investigator evaluation of cosmetic characteristics of the products and global product assessment were positive for both mousses. The use of a foam may be useful in cAD to improve both skin lesions and pruritus. Both foams evaluated in this study were equally effective. This method of product delivery is easy to use for owners which is important to improve compliance in practice.